



ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY

VOLUME 40, 2000

ARTHUR K. CHO, *Editor*

University of California School of Medicine, Los Angeles

TERRENCE F. BLASCHKE, *Associate Editor*

Stanford University Medical Center, Stanford

ING K. HO, *Associate Editor*

University of Mississippi Medical Center, Jackson

HORACE H. LOH, *Associate Editor*

University of Minnesota Medical School, Minneapolis

www.AnnualReviews.org

science@annurev.org

650-493-4400

ANNUAL REVIEWS

4139 El Camino Way • P.O. Box 10139 • Palo Alto, California 94303-0139

CONTENTS

TARGETS OF DRUG ACTION, <i>A.S.V. Burgen</i>	1
LABORATORY OF CHEMICAL PHARMACOLOGY, NATIONAL HEART, LUNG, AND BLOOD INSTITUTE, NIH: A SHORT HISTORY, <i>James R. Gillette</i>	19
CHLORINATED METHANES AND LIVER INJURY: HIGHLIGHTS OF THE PAST 50 YEARS, <i>Gabriel L. Plaa</i>	43
PHARMACOKINETIC/PHARMACODYNAMIC MODELING IN DRUG DEVELOPMENT, <i>L. B. Sheiner and J-L. Steimer</i>	67
SEQUENCING THE ENTIRE GENOMES OF FREE-LIVING ORGANISMS: THE FOUNDATION OF PHARMACOLOGY IN THE NEW MILLENNIUM, <i>Samuel Broder and J. Craig Venter</i>	97
HIGH-THROUGHPUT SCREENING IN DRUG METABOLISM AND PHARMACOKINETIC SUPPORT OF DRUG DISCOVERY, <i>Ronald E. White</i>	133
PHARMACOGENETICS OF SULFOTRANSFERASE, <i>K. Nagata and Y. Yamazoe</i>	159
DRUG DISCOVERY IN THE NEXT MILLENNIUM, <i>Eliot H. Ohlstein, Robert R. Ruffolo Jr, and John D. Elliott</i>	177
THE IMPACT OF GENOMICS ON DRUG DISCOVERY, <i>C. Debouck and B. Metcalf</i>	193
SIMULATION OF CLINICAL TRIALS, <i>N. H. G. Holford, H. C. Kimko, J. P. R. Monteleone, and Carl C. Peck</i>	209
THE REGULATOR OF G PROTEIN SIGNALING FAMILY, <i>Luc De Vries, Bin Zheng, Thierry Fischer, Eric Elenko, and Marilyn G. Farquhar</i>	235
PARALLEL ARRAY AND MIXTURE-BASED SYNTHETIC COMBINATORIAL CHEMISTRY: TOOLS FOR THE NEXT MILLENNIUM, <i>Richard A. Houghten</i>	273
PHARMACOLOGY OF SELECTIN INHIBITORS IN ISCHEMIA/REPERFUSION STATES, <i>David J. Lefer</i>	283
A NOVEL MEANS OF DRUG DELIVERY: MYOBLAST-MEDIATED GENE THERAPY AND REGULATABLE RETROVIRAL VECTORS, <i>Clare R. Ozawa, Matthew L. Springer, and Helen M. Blau</i>	295
5-HT ₆ RECEPTORS AS EMERGING TARGETS FOR DRUG DISCOVERY, <i>Theresa A. Branchek and Thomas P. Blackburn</i>	319

THE IMPACT OF GENOMICS-BASED TECHNOLOGIES ON DRUG SAFETY EVALUATION, <i>Jeffrey F. Waring and Roger G. Ulrich</i>	335
MITOCHONDRIAL TARGETS OF DRUG TOXICITY, <i>K. B. Wallace and A. A. Starkov</i>	353
MOLECULAR MECHANISMS AND REGULATION OF OPIOID RECEPTOR SIGNALING, <i>Ping-Yee Law, Yung H. Wong, and Horace H. Loh</i>	389
NICOTINIC RECEPTORS AT THE AMINO ACID LEVEL, <i>Pierre-Jean Corringer, Nicolas Le Novère, and Jean-Pierre Changeux</i>	431
THE ROLE OF RHO IN G PROTEIN COUPLED RECEPTOR SIGNAL TRANSDUCTION, <i>Valerie P. Sah, Tammy M. Seasholtz, Sarah A. Sagi, and Joan Heller Brown</i>	459
CENTRAL ROLE OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS IN THE ACTIONS OF PEROXISOME PROLIFERATORS, <i>J. Christopher Corton, Steven P. Anderson, and Anja Stauber</i>	491
THE PAS SUPERFAMILY: SENSORS OF ENVIRONMENTAL AND DEVELOPMENTAL SIGNALS, <i>Yi-Zhong Gu, John B. Hogenesch, and Christopher A. Bradfield</i>	519
PHARMACOLOGY OF CLONED P2X RECEPTORS, <i>R. Alan North and Annmarie Surprenant</i>	563
HUMAN UDP-GLUCURONOSYLTRANSFERASES: METABOLISM, EXPRESSION, AND DISEASE, <i>Robert H. Tukey and Christian P. Strassburg</i>	581
14-3-3 PROTEINS: STRUCTURE, FUNCTION, AND REGULATIONS, <i>Haian Fu, Romesh R. Subramanian, and Shane C. Masters</i>	617
DUAL PROTEASE INHIBITOR THERAPY IN HIV-INFECTED PATIENTS: PHARMACOLOGIC RATIONALE AND CLINICAL BENEFITS, <i>Charles Flexner</i>	649
INDEXES	
Subject Index	675
Cumulative Index of Contributing Authors, Volumes 36–40	687
Cumulative Index of Chapter Titles, Volumes 36–40	690